IRMD Quote, Financials, Valuation and Earnings

Electromed, Inc. has a net margin of 26.3% compared to IRadimed Corp.'s net margin of 12.65%. IRadimed Corp.'s return on equity of 23.39% beat Electromed, Inc.'s return on equity of 18.89%.

IRadimed Corp. has a consensus price target of $86.50, signalling upside risk potential of 1.86%. On the other hand Electromed, Inc. has an analysts' consensus of $36.00 which suggests that it could grow by 25.79%. Given that Electromed, Inc. has higher upside potential than IRadimed Corp., analysts believe Electromed, Inc. is more attractive than IRadimed Corp..

IRadimed Corp. has a beta of 1.064, which suggesting that the stock is 6.371% more volatile than S&P 500. In comparison Electromed, Inc. has a beta of 0.259, suggesting its less volatile than the S&P 500 by 74.113%.

IRadimed Corp. has a quarterly dividend of $0.50 per share corresponding to a yield of 0.7%. Electromed, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. IRadimed Corp. pays 29.91% of its earnings as a dividend. Electromed, Inc. pays out -- of its earnings as a dividend. IRadimed Corp.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

IRadimed Corp. quarterly revenues are $21.2M, which are larger than Electromed, Inc. quarterly revenues of $16.9M. IRadimed Corp.'s net income of $5.6M is higher than Electromed, Inc.'s net income of $2.1M. Notably, IRadimed Corp.'s price-to-earnings ratio is 58.88x while Electromed, Inc.'s PE ratio is 30.79x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for IRadimed Corp. is 15.49x versus 3.82x for Electromed, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

IRIDEX Corp. has a net margin of 26.3% compared to IRadimed Corp.'s net margin of -12.6%. IRadimed Corp.'s return on equity of 23.39% beat IRIDEX Corp.'s return on equity of -155.93%.

IRadimed Corp. has a consensus price target of $86.50, signalling upside risk potential of 1.86%. On the other hand IRIDEX Corp. has an analysts' consensus of -- which suggests that it could grow by 100%. Given that IRIDEX Corp. has higher upside potential than IRadimed Corp., analysts believe IRIDEX Corp. is more attractive than IRadimed Corp..

IRadimed Corp. has a beta of 1.064, which suggesting that the stock is 6.371% more volatile than S&P 500. In comparison IRIDEX Corp. has a beta of 0.652, suggesting its less volatile than the S&P 500 by 34.842%.

IRadimed Corp. has a quarterly dividend of $0.50 per share corresponding to a yield of 0.7%. IRIDEX Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. IRadimed Corp. pays 29.91% of its earnings as a dividend. IRIDEX Corp. pays out -- of its earnings as a dividend. IRadimed Corp.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

IRadimed Corp. quarterly revenues are $21.2M, which are larger than IRIDEX Corp. quarterly revenues of $12.5M. IRadimed Corp.'s net income of $5.6M is higher than IRIDEX Corp.'s net income of -$1.6M. Notably, IRadimed Corp.'s price-to-earnings ratio is 58.88x while IRIDEX Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for IRadimed Corp. is 15.49x versus 0.33x for IRIDEX Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Myomo, Inc. has a net margin of 26.3% compared to IRadimed Corp.'s net margin of -36.3%. IRadimed Corp.'s return on equity of 23.39% beat Myomo, Inc.'s return on equity of -68.35%.

IRadimed Corp. has a consensus price target of $86.50, signalling upside risk potential of 1.86%. On the other hand Myomo, Inc. has an analysts' consensus of $5.00 which suggests that it could grow by 436.19%. Given that Myomo, Inc. has higher upside potential than IRadimed Corp., analysts believe Myomo, Inc. is more attractive than IRadimed Corp..

IRadimed Corp. has a beta of 1.064, which suggesting that the stock is 6.371% more volatile than S&P 500. In comparison Myomo, Inc. has a beta of 1.026, suggesting its more volatile than the S&P 500 by 2.583%.

IRadimed Corp. has a quarterly dividend of $0.50 per share corresponding to a yield of 0.7%. Myomo, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. IRadimed Corp. pays 29.91% of its earnings as a dividend. Myomo, Inc. pays out -- of its earnings as a dividend. IRadimed Corp.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

IRadimed Corp. quarterly revenues are $21.2M, which are larger than Myomo, Inc. quarterly revenues of $10.1M. IRadimed Corp.'s net income of $5.6M is higher than Myomo, Inc.'s net income of -$3.7M. Notably, IRadimed Corp.'s price-to-earnings ratio is 58.88x while Myomo, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for IRadimed Corp. is 15.49x versus 0.92x for Myomo, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Stereotaxis, Inc. has a net margin of 26.3% compared to IRadimed Corp.'s net margin of -86.59%. IRadimed Corp.'s return on equity of 23.39% beat Stereotaxis, Inc.'s return on equity of -218.3%.

IRadimed Corp. has a consensus price target of $86.50, signalling upside risk potential of 1.86%. On the other hand Stereotaxis, Inc. has an analysts' consensus of $4.20 which suggests that it could grow by 79.49%. Given that Stereotaxis, Inc. has higher upside potential than IRadimed Corp., analysts believe Stereotaxis, Inc. is more attractive than IRadimed Corp..

IRadimed Corp. has a beta of 1.064, which suggesting that the stock is 6.371% more volatile than S&P 500. In comparison Stereotaxis, Inc. has a beta of 1.472, suggesting its more volatile than the S&P 500 by 47.244%.

IRadimed Corp. has a quarterly dividend of $0.50 per share corresponding to a yield of 0.7%. Stereotaxis, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. IRadimed Corp. pays 29.91% of its earnings as a dividend. Stereotaxis, Inc. pays out -- of its earnings as a dividend. IRadimed Corp.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

IRadimed Corp. quarterly revenues are $21.2M, which are larger than Stereotaxis, Inc. quarterly revenues of $7.5M. IRadimed Corp.'s net income of $5.6M is higher than Stereotaxis, Inc.'s net income of -$6.5M. Notably, IRadimed Corp.'s price-to-earnings ratio is 58.88x while Stereotaxis, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for IRadimed Corp. is 15.49x versus 6.90x for Stereotaxis, Inc.. Usually stocks with elevated PS ratios are considered overvalued.